Skip to main content
SpringerLink
Log in

Imatinib: profile report

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lyseng-Williams K, Jarvis B. Imatinib. Drugs 2001; 61(12): 1765–74

    Article  Google Scholar 

  2. Goldman JM. Imatinib: a viewpoint. Drugs 2001; 61(12): 1765–74

    Article  Google Scholar 

  3. Druker BJ. Imatinib: a viewpoint. Drugs 2001; 61(12): 1765–74

    Article  Google Scholar 

  4. Mauro M, Druker B. Chronic myelogenous leukemia. Curr Opin Oncol 2001 Jan; 13(1): 3–7

    Article  PubMed  CAS  Google Scholar 

  5. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999 Apr 29; 340: 1330–40

    Article  PubMed  CAS  Google Scholar 

  6. Novartis Pharmaceuticals Corporation. Gleevec (imatinib mesylate) capsules prescribing information. East Hanover, (NJ): May 2001

  7. Hochhaus A, Kantarjian H, Sawyers C, et al. Glivec (imatinib mesylate, STI571) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study [abstract no. 736]. 6th European Haematology Assn Meeting; 2001 Jun 21–24; Frankfurt

  8. Goldman J, Talpaz M, Silver R, et al. Treatment of adult Philadelphia chromosome positive chronic myeloid leukaemia (CML) in accelerated phase with STI571: update of phase II results [abstract no. 737]. 6th European Haematology Assn Meeting; 2001 Jun 21–24; Frankfurt

    Google Scholar 

  9. Hochhaus A, Sawyers C, Feldman E, et al. Glivec (imatinib mesylate, STI571) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a multicenter phase II study [abstract no. 049]. 6th European Haematology Association Meeting; 2001 Jun 21–24; Frankfurt

    Google Scholar 

  10. Ottmann OG, Sawyers C, Druker B, et al. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias. Blood 2000 Nov 16; 96(11 Pt 1): 828

    Google Scholar 

  11. Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117) [abstract no. 1]. J Clin Oncol 2001 May 12; 20(Pt 1): 1a

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imatinib: profile report. Drugs Ther. Perspect 18, 5–6 (2002). https://doi.org/10.2165/00042310-200218030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218030-00002

Keywords

Search

Navigation